

a.) REMARKS


In the outstanding Office Action, the Examiner has requested that Applicants elect for prosecution one of the inventions (Groups I-XIII) noted on pages 2-4 of the Office Action.

In response, Applicants hereby elect to prosecute the invention of Group IV, namely Claims 6-9 drawn to a pharmaceutical composition that destroys malignant kidney tissue comprising a hybrid molecular structure of a molecule that specifically targets CD70 linked to a cellular killing agent.<sup>1</sup> As noted, rejoinder of appropriate process claims is respectfully requested upon the allowance of an elected product claim.

Entry hereof is earnestly solicited.

Applicants' undersigned attorney may be reached in our New York office by telephone at (212) 218-2100. All correspondence should continue to be directed to our below listed address.

Respectfully submitted,



Lawrence S. Perry  
Attorney for Applicants  
Registration No. 31,865

FITZPATRICK, CELLA, HARPER & SCINTO  
30 Rockefeller Plaza  
New York, New York 10112-3801  
Facsimile: (212) 218-2200

LSP\ac

NY\_Main 542064\_1

---

<sup>1</sup> The Examiner noted that, if Groups III, V, or VI are elected, a further selection of a species for search among: cytotoxic agent, radioactive agent, calicheamicin and a calicheamicin derivative is required. However, no response is required since none of the Groups III, V or VI was elected.